

# Novavax to Host Conference Call to Discuss Third Quarter 2022 Financial Results and Operational Highlights on November 8, 2022

November 1, 2022

GAITHERSBURG, Md., Nov. 1, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced it will report its third quarter 2022 financial results and operational highlights on Tuesday, November 8, 2022, following the close of U.S. financial markets. Details of the event and replay are as follows:

#### Conference call details:

Date: November 8, 2022  
Time: 4:30 p.m. U.S. Eastern Daylight Time (EDT)  
Dial-in number: 833) 974-2381 (Domestic) or (412) 317-5774 (International)  
Webcast: [ir.novavax.com/events](https://ir.novavax.com/events)

- Participants will be prompted to request to join the Novavax, Inc. call.
- To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast.

#### Replay details:

Date: Available starting at 7:30 p.m. EDT, November 8, 2022 until 11:59 p.m. U.S. EDT, November 15, 2022  
Dial-in number: (877) 344-7529 (Domestic) or (412) 317-0088 (International)  
Passcode: 3408655  
Webcast: [ir.novavax.com/events](https://ir.novavax.com/events), until February 8, 2023

## About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. The Novavax COVID-19 vaccine has received authorization from multiple regulatory authorities globally, including the U.S. Food and Drug Administration, the European Commission, and the WHO. The vaccine is currently under review by multiple regulatory agencies worldwide, including for additional populations and indications such as adolescents and as a booster. In addition to its COVID-19 vaccine, Novavax is also currently evaluating its CIC vaccine candidate in a Phase 1/2 clinical trial, its quadrivalent influenza investigational vaccine candidate, and an Omicron strain-based vaccine (NVX-CoV2515) as well as a bivalent format Omicron-based / original strain-based vaccine. These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

For more information, visit? [www.novavax.com](https://www.novavax.com)? and connect with us on [LinkedIn](#).

#### Contacts:

##### Investors

Erika Schultz | 240-268-2022

[ir@novavax.com](mailto:ir@novavax.com)

##### Media

Ali Chartan or Giovanna Chandler | 202-709-5563

[media@novavax.com](mailto:media@novavax.com)

SOURCE Novavax, Inc.

Image not found or type unknown